Logo image of AYTU

AYTU BIOPHARMA INC (AYTU) Stock Fundamental Analysis

NASDAQ:AYTU - US0547548588 - Common Stock

2.26 USD
-0.08 (-3.42%)
Last: 9/4/2025, 8:00:01 PM
2.22 USD
-0.04 (-1.77%)
After Hours: 9/4/2025, 8:00:01 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to AYTU. AYTU was compared to 195 industry peers in the Pharmaceuticals industry. AYTU has a medium profitability rating, but doesn't score so well on its financial health evaluation. AYTU is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

AYTU had negative earnings in the past year.
In the past year AYTU has reported a negative cash flow from operations.
In the past 5 years AYTU always reported negative net income.
In the past 5 years AYTU always reported negative operating cash flow.
AYTU Yearly Net Income VS EBIT VS OCF VS FCFAYTU Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

AYTU's Return On Assets of 1.32% is amongst the best of the industry. AYTU outperforms 82.05% of its industry peers.
AYTU's Return On Equity of 4.70% is amongst the best of the industry. AYTU outperforms 84.10% of its industry peers.
AYTU has a Return On Invested Capital of 0.46%. This is in the better half of the industry: AYTU outperforms 77.44% of its industry peers.
Industry RankSector Rank
ROA 1.32%
ROE 4.7%
ROIC 0.46%
ROA(3y)-35%
ROA(5y)-27.17%
ROE(3y)-112.19%
ROE(5y)-78.65%
ROIC(3y)N/A
ROIC(5y)N/A
AYTU Yearly ROA, ROE, ROICAYTU Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

1.3 Margins

AYTU has a better Profit Margin (2.37%) than 81.03% of its industry peers.
Looking at the Operating Margin, with a value of 0.53%, AYTU is in the better half of the industry, outperforming 77.44% of the companies in the same industry.
AYTU has a Gross Margin of 68.59%. This is in the better half of the industry: AYTU outperforms 76.41% of its industry peers.
In the last couple of years the Gross Margin of AYTU has remained more or less at the same level.
Industry RankSector Rank
OM 0.53%
PM (TTM) 2.37%
GM 68.59%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y14.82%
GM growth 5Y-0.72%
AYTU Yearly Profit, Operating, Gross MarginsAYTU Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K -2.5K

More info and screens

1

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), AYTU is destroying value.
AYTU has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, AYTU has more shares outstanding
AYTU has a worse debt/assets ratio than last year.
AYTU Yearly Shares OutstandingAYTU Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M
AYTU Yearly Total Debt VS Total AssetsAYTU Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -2.82, we must say that AYTU is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -2.82, AYTU perfoms like the industry average, outperforming 45.64% of the companies in the same industry.
A Debt/Equity ratio of 0.56 indicates that AYTU is somewhat dependend on debt financing.
AYTU has a worse Debt to Equity ratio (0.56) than 63.08% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.56
Debt/FCF N/A
Altman-Z -2.82
ROIC/WACC0.03
WACC16.54%
AYTU Yearly LT Debt VS Equity VS FCFAYTU Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

AYTU has a Current Ratio of 1.03. This is a normal value and indicates that AYTU is financially healthy and should not expect problems in meeting its short term obligations.
AYTU's Current ratio of 1.03 is on the low side compared to the rest of the industry. AYTU is outperformed by 80.51% of its industry peers.
AYTU has a Quick Ratio of 1.03. This is a bad value and indicates that AYTU is not financially healthy enough and could expect problems in meeting its short term obligations.
AYTU's Quick ratio of 0.87 is on the low side compared to the rest of the industry. AYTU is outperformed by 78.97% of its industry peers.
Industry RankSector Rank
Current Ratio 1.03
Quick Ratio 0.87
AYTU Yearly Current Assets VS Current LiabilitesAYTU Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 57.03% over the past year.
Looking at the last year, AYTU shows a very negative growth in Revenue. The Revenue has decreased by -26.17% in the last year.
The Revenue has been growing by 61.82% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)57.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%140.38%
Revenue 1Y (TTM)-26.17%
Revenue growth 3Y7.28%
Revenue growth 5Y61.82%
Sales Q2Q%2.55%

3.2 Future

The Earnings Per Share is expected to grow by 30.75% on average over the next years. This is a very strong growth
Based on estimates for the next years, AYTU will show a quite strong growth in Revenue. The Revenue will grow by 9.72% on average per year.
EPS Next Y121.58%
EPS Next 2Y30.26%
EPS Next 3Y30.75%
EPS Next 5YN/A
Revenue Next Year-14.97%
Revenue Next 2Y-6.87%
Revenue Next 3Y6.76%
Revenue Next 5Y9.72%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
AYTU Yearly Revenue VS EstimatesAYTU Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M
AYTU Yearly EPS VS EstimatesAYTU Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -50K -100K -150K

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

AYTU reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year AYTU is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AYTU Price Earnings VS Forward Price EarningsAYTU Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, AYTU is valued cheaper than 100.00% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 2.11
AYTU Per share dataAYTU EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

A more expensive valuation may be justified as AYTU's earnings are expected to grow with 30.75% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.26%
EPS Next 3Y30.75%

More info and screens

0

5. Dividend

5.1 Amount

AYTU does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AYTU BIOPHARMA INC

NASDAQ:AYTU (9/4/2025, 8:00:01 PM)

After market: 2.22 -0.04 (-1.77%)

2.26

-0.08 (-3.42%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-14 2025-05-14/amc
Earnings (Next)09-25 2025-09-25/amc
Inst Owners27.72%
Inst Owner Change80.96%
Ins Owners8.18%
Ins Owner Change0.54%
Market Cap20.29M
Analysts82.5
Price Target9.86 (336.28%)
Short Float %5.73%
Short Ratio3.09
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)115.04%
Min EPS beat(2)8.96%
Max EPS beat(2)221.11%
EPS beat(4)3
Avg EPS beat(4)40.1%
Min EPS beat(4)-78.65%
Max EPS beat(4)221.11%
EPS beat(8)6
Avg EPS beat(8)-402.91%
EPS beat(12)8
Avg EPS beat(12)-280.54%
EPS beat(16)9
Avg EPS beat(16)-239.81%
Revenue beat(2)2
Avg Revenue beat(2)16.96%
Min Revenue beat(2)2.24%
Max Revenue beat(2)31.67%
Revenue beat(4)3
Avg Revenue beat(4)8.11%
Min Revenue beat(4)-3.7%
Max Revenue beat(4)31.67%
Revenue beat(8)6
Avg Revenue beat(8)3.06%
Revenue beat(12)8
Avg Revenue beat(12)1.57%
Revenue beat(16)9
Avg Revenue beat(16)0.32%
PT rev (1m)7.41%
PT rev (3m)20.83%
EPS NQ rev (1m)18.51%
EPS NQ rev (3m)-106.92%
EPS NY rev (1m)-8.33%
EPS NY rev (3m)-15.97%
Revenue NQ rev (1m)0.38%
Revenue NQ rev (3m)-8.59%
Revenue NY rev (1m)0.11%
Revenue NY rev (3m)3.06%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.29
P/FCF N/A
P/OCF N/A
P/B 0.58
P/tB N/A
EV/EBITDA 2.11
EPS(TTM)-1.13
EYN/A
EPS(NY)-0.87
Fwd EYN/A
FCF(TTM)-0.64
FCFYN/A
OCF(TTM)-0.62
OCFYN/A
SpS7.71
BVpS3.89
TBVpS-1.54
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 1.32%
ROE 4.7%
ROCE 0.69%
ROIC 0.46%
ROICexc 0.64%
ROICexgc N/A
OM 0.53%
PM (TTM) 2.37%
GM 68.59%
FCFM N/A
ROA(3y)-35%
ROA(5y)-27.17%
ROE(3y)-112.19%
ROE(5y)-78.65%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y14.82%
GM growth 5Y-0.72%
F-Score4
Asset Turnover0.56
Health
Industry RankSector Rank
Debt/Equity 0.56
Debt/FCF N/A
Debt/EBITDA 3.06
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage 0.13
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.03
Quick Ratio 0.87
Altman-Z -2.82
F-Score4
WACC16.54%
ROIC/WACC0.03
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)57.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%140.38%
EPS Next Y121.58%
EPS Next 2Y30.26%
EPS Next 3Y30.75%
EPS Next 5YN/A
Revenue 1Y (TTM)-26.17%
Revenue growth 3Y7.28%
Revenue growth 5Y61.82%
Sales Q2Q%2.55%
Revenue Next Year-14.97%
Revenue Next 2Y-6.87%
Revenue Next 3Y6.76%
Revenue Next 5Y9.72%
EBIT growth 1Y-80.87%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year414.22%
EBIT Next 3Y131.97%
EBIT Next 5Y106.24%
FCF growth 1Y73.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y74.38%
OCF growth 3YN/A
OCF growth 5YN/A